Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Зуд у пациентов онкологического профиля как полиэтиологический симптом
Зуд у пациентов онкологического профиля как полиэтиологический симптом
Миченко А.В., Львов А.Н., Круглова Л.С., Романов Д.В., Кузьма Е.А. Зуд у пациентов онкологического профиля как полиэтиологический симптом. Consilium Medicum. 2022;24(8):504–510.
DOI: 10.26442/20751753.2022.8.201810
© ООО «КОНСИЛИУМ МЕДИКУМ», 2022 г.
DOI: 10.26442/20751753.2022.8.201810
© ООО «КОНСИЛИУМ МЕДИКУМ», 2022 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Зуд является одним из субъективных ощущений, значительно снижающих качество жизни пациентов. У больных со злокачественными новообразованиями зуд может быть обусловлен рядом универсальных либо специфических для пациентов онкологического профиля патофизиологических факторов. В настоящей статье рассматриваются расстройства, вызывающие зуд у онкологических пациентов: собственно рост новообразования, общие патофизиологические изменения, ассоциированные с рядом злокачественных новообразований, паранеоплазия, противоопухолевая терапия, сопутствующие дерматозы, системные заболевания, психосоматические расстройства. Представлены известные либо предполагаемые механизмы развития зуда при каждом из упомянутых провоцирующих зуд факторов, описаны применяемые методы коррекции зуда в зависимости от причины, его вызвавшей. В завершение статьи представлены универсальные методы коррекции зуда, применимые у пациентов онкологического профиля независимо от пруритогенного фактора, особое внимание уделено коррекции ксероза как универсальной причины зуда у онкологических пациентов.
Ключевые слова: зуд, злокачественные опухоли, паранеоплазия, зуд у онкологических пациентов, ксероз
Keywords: pruritus, malignant tumors, paraneoplasia, pruritus in cancer patients, xerosis
Ключевые слова: зуд, злокачественные опухоли, паранеоплазия, зуд у онкологических пациентов, ксероз
________________________________________________
Keywords: pruritus, malignant tumors, paraneoplasia, pruritus in cancer patients, xerosis
Полный текст
Список литературы
1. Dickison P, Swain G, Peek JJ, Smith SD. Itching for answers: Prevalence and severity of pruritus in psoriasis. Australas J Dermatol. 2018;59(3):206-9. DOI:10.1111/ajd.12747
2. Pavlis J, Yosipovitch G. Management of Itch in Atopic Dermatitis. Am J Clin Dermatol. 2018;19(3):319‑32. DOI:10.1007/s40257-017-0335-4
3. Lim YL, Chan YH, Yosipovitch G, Greaves MW. Pruritus is a common and significant symptom of acne. J Eur Acad Dermatol Venereol. 2008;22(11):1332-6.
DOI:10.1111/j.1468-3083.2008.02828.x
4. Rowe B, Yosipovitch G. Malignancy-associated pruritus. Eur J Pain. 2016;20(1):19-23. DOI:10.1002/ejp.760
5. Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol. 2012;67(4):760-8. DOI:10.1016/j.jaad.2011.12.021
6. Mills KC, Kwatra SG, Feneran AN, et al. Itch and pain in nonmelanoma skin cancer: pain as an important feature of cutaneous squamous cell carcinoma. Arch Dermatol. 2012;148(12):1422-3. DOI:10.1001/archdermatol.2012.3104
7. Chiang HC, Huang V, Cornelius LA. Cancer and itch. Semin Cutan Med Surg. 2011;30(2):107-12. DOI:10.1016/j.sder.2011.05.003
8. Lacouture ME (ed.). Dermatologic Principles and Practice in Oncology. 2014.
9. Миченко А.В., Круглова Л.С., Шатохина Е.А., и др. Дерматологическая токсичность ингибиторов EGFR: патогенетическое обоснование и алгоритм коррекции акнеподобной сыпи. Онкогематология. 2021;16(4):50-8 [Michenko AV, Kruglova LS, Shatokhina EA, et al. Dermatologicheskaia toksichnost' ingibitorov EGFR: patogeneticheskoe obosnovanie i algoritm korrektsii aknepodobnoi sypi. Onkogematologiia. 2021;16(4):50-8 (in Russian)]. DOI:10.17650/1818-8346-2021-16-4-50-58
10. Yosipovitch G. Chronic pruritus: A paraneoplastic sign. Dermatol Ther. 2010;23:590-6.
11. Jones EA, Bergasa NV. Why do cholestatic patients itch? Gut. 1996;38:644-5.
12. Wang H, Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol. 2010;49:1-11.
13. Naser AY, Hameed AN, Mustafa N, et al. Depression and Anxiety in Patients With Cancer: A Cross-Sectional Study. Front Psychol. 2021;12:585534. DOI:10.3389/fpsyg.2021.585534
14. Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment (Review). Oncol Lett. 2015;9(4):1509-14. DOI:10.3892/ol.2015.2944
15. Schmelz M, Schmidt R, Weidner C, et al. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol. 2003;89:2441-8.
16. Steinhoff M, Bienenstock J, Schmelz M, et al. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol. 2006;126:1705-18.
17. Parker F. Structure and function of skin. In: Goldma L, Bennett JC (ed.). Cecil Textbook of Medicine. 21st ed. Philadelphia: Saunders, 2000; p. 2266.
18. Mir A, Agim NG, Kane AA, et al. Giant Congenital Melanocytic Nevus Treated With Trametinib. Pediatrics. 2019;143(3):e20182469. DOI:10.1542/peds.2018-2469
19. Yuan T, Lu XH, Tang B Mr, et al. Differences in clinical characteristics and lesion proteomics between inflammatory linear verrucous epidermal nevus and local verrucous epidermal nevus. J Proteomics. 2022;260:104554. DOI:10.1016/j.jprot.2022.104554
20. Veraldi S, Bocor M, Gianotti R, Gasparini G. Multiple eruptive dermatofibromas localized exclusively to the buttock. Int J Dermatol. 1991;30(7):507-8.
DOI:10.1111/j.1365-4362.1991.tb04875.x
21. Husain Z, Ho JK, Hantash BM. Sign and pseudo-sign of Leser-Trélat: case reports and a review of the literature. J Drugs Dermatol. 2013;12(5):e79-87. PMID: 23652964.
22. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010;40(9):828-34. DOI:10.1111/j.1365-2362.2010.02334.x
23. Villafranca JJ, Siles MG, Casanova M, et al. Paraneoplastic pruritus presenting with Hodgkin’s lymphoma: a case report. J Med Case Rep. 2014;8:300. DOI:10.1186/1752-1947-8-300
24. Meyer N, Paul C, Misery L. Pruritus in Cutaneous T-cell Lymphomas: Frequent, Often Severe and Difficult to Treat. Acta Derm Venereol. 2010;90:12-7. DOI:10.2340/00015555-0789
25. Dummer R, Heald PW, Nestle FO, et al. Sezary syndrome T-cells clones display T-helper2 cytokines and express the accessory factor-1 (interferon gamma receptor beta-chain). Blood. 1996;88:1383-9.
26. Yamamoto T, Katayama I, Nishioka N. Role of mast cell and stem cell factor in hyperpigmented mycosis fungoides. Blood. 1997;90:1338-40.
27. Vermeer MH, Willemze R. Is Mycosis Fungoides exacerbated by fluoxetine? J Am Acad Dermatol. 1996;35:635-6.
28. Brandes LJ, La Bella FS, Warrington FC. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonist. J Natl Cancer Inst. 1991;83:1329-36.
29. Yosipovitch G, Szolar C, Hui XY, Maibach H. High-potency topical corticosteroid rapidly decrease histamine-induced itch but not thermal sensation and pain in human beings. J Am Acad Dermatol. 1996;35:118-20.
30. Bingham LG, Noble JW, Davis MD. Wet dressing used with topical corticosteroids for pruritic dermatoses: a retrospective study. J Am Acad Dermatol. 2009;60:792-800.
31. Phan NQ, Bernhard JD, Luger TA, et al. Antipruritic treatment with systemic mu-opioid receptor antagonists: A review. J Am Acad Dermatol. 2009;63:680-8.
32. Lidstone V, Thorns A. Pruritus in cancer patients. Cancer Treat Rev. 2001;27:305-12.
33. Barrios DM, Phillips GS, Geisler AN, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol. 2021;32(6):736-45.
34. Askling J, Linet M, Gridley G, et al. Cancer incidence in a population based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology. 2002;123:1428-35.
35. Pacheco M, Ferreira H, Silva C, et al. Antinuclear Antibody (ANA) and Anti-Mi-2-Alpha Positive Dermatomyositis Hinting a Cancer Diagnosis. Cureus. 2022;14(2):e21844. DOI:10.7759/cureus.21844
36. Sanders KM, Akiyama T. The vicious cycle of itch and anxiety. Neurosci Biobehav Rev. 2018;87:17-26.
37. Reich A, Trybucka K, Tracinska A, et al. Acne Itch: Do Acne Patients Suffer From Itching? Acta Derm Venereol. 2008;88(1):38-42.
38. Seité S, Moyal D. Using an emollient lotion to improve objective and subjective symptoms in atopic patients. 24th World Congress of dermatology. Abstract book. Milan, 2022.
39. Wohlrab J, Bangemann N, Kleine-Tebbe A, et al. Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer. Breast Cancer (Dove Med Press). 2014;6:115-22. DOI:10.2147/BCTT.S61699
2. Pavlis J, Yosipovitch G. Management of Itch in Atopic Dermatitis. Am J Clin Dermatol. 2018;19(3):319‑32. DOI:10.1007/s40257-017-0335-4
3. Lim YL, Chan YH, Yosipovitch G, Greaves MW. Pruritus is a common and significant symptom of acne. J Eur Acad Dermatol Venereol. 2008;22(11):1332-6.
DOI:10.1111/j.1468-3083.2008.02828.x
4. Rowe B, Yosipovitch G. Malignancy-associated pruritus. Eur J Pain. 2016;20(1):19-23. DOI:10.1002/ejp.760
5. Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol. 2012;67(4):760-8. DOI:10.1016/j.jaad.2011.12.021
6. Mills KC, Kwatra SG, Feneran AN, et al. Itch and pain in nonmelanoma skin cancer: pain as an important feature of cutaneous squamous cell carcinoma. Arch Dermatol. 2012;148(12):1422-3. DOI:10.1001/archdermatol.2012.3104
7. Chiang HC, Huang V, Cornelius LA. Cancer and itch. Semin Cutan Med Surg. 2011;30(2):107-12. DOI:10.1016/j.sder.2011.05.003
8. Lacouture ME (ed.). Dermatologic Principles and Practice in Oncology. 2014.
9. Michenko AV, Kruglova LS, Shatokhina EA, et al. Dermatologicheskaia toksichnost' ingibitorov EGFR: patogeneticheskoe obosnovanie i algoritm korrektsii aknepodobnoi sypi. Onkogematologiia. 2021;16(4):50-8 (in Russian). DOI:10.17650/1818-8346-2021-16-4-50-58
10. Yosipovitch G. Chronic pruritus: A paraneoplastic sign. Dermatol Ther. 2010;23:590-6.
11. Jones EA, Bergasa NV. Why do cholestatic patients itch? Gut. 1996;38:644-5.
12. Wang H, Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol. 2010;49:1-11.
13. Naser AY, Hameed AN, Mustafa N, et al. Depression and Anxiety in Patients With Cancer: A Cross-Sectional Study. Front Psychol. 2021;12:585534. DOI:10.3389/fpsyg.2021.585534
14. Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment (Review). Oncol Lett. 2015;9(4):1509-14. DOI:10.3892/ol.2015.2944
15. Schmelz M, Schmidt R, Weidner C, et al. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol. 2003;89:2441-8.
16. Steinhoff M, Bienenstock J, Schmelz M, et al. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol. 2006;126:1705-18.
17. Parker F. Structure and function of skin. In: Goldma L, Bennett JC (ed.). Cecil Textbook of Medicine. 21st ed. Philadelphia: Saunders, 2000; p. 2266.
18. Mir A, Agim NG, Kane AA, et al. Giant Congenital Melanocytic Nevus Treated With Trametinib. Pediatrics. 2019;143(3):e20182469. DOI:10.1542/peds.2018-2469
19. Yuan T, Lu XH, Tang B Mr, et al. Differences in clinical characteristics and lesion proteomics between inflammatory linear verrucous epidermal nevus and local verrucous epidermal nevus. J Proteomics. 2022;260:104554. DOI:10.1016/j.jprot.2022.104554
20. Veraldi S, Bocor M, Gianotti R, Gasparini G. Multiple eruptive dermatofibromas localized exclusively to the buttock. Int J Dermatol. 1991;30(7):507-8.
DOI:10.1111/j.1365-4362.1991.tb04875.x
21. Husain Z, Ho JK, Hantash BM. Sign and pseudo-sign of Leser-Trélat: case reports and a review of the literature. J Drugs Dermatol. 2013;12(5):e79-87. PMID: 23652964.
22. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010;40(9):828-34. DOI:10.1111/j.1365-2362.2010.02334.x
23. Villafranca JJ, Siles MG, Casanova M, et al. Paraneoplastic pruritus presenting with Hodgkin’s lymphoma: a case report. J Med Case Rep. 2014;8:300. DOI:10.1186/1752-1947-8-300
24. Meyer N, Paul C, Misery L. Pruritus in Cutaneous T-cell Lymphomas: Frequent, Often Severe and Difficult to Treat. Acta Derm Venereol. 2010;90:12-7. DOI:10.2340/00015555-0789
25. Dummer R, Heald PW, Nestle FO, et al. Sezary syndrome T-cells clones display T-helper2 cytokines and express the accessory factor-1 (interferon gamma receptor beta-chain). Blood. 1996;88:1383-9.
26. Yamamoto T, Katayama I, Nishioka N. Role of mast cell and stem cell factor in hyperpigmented mycosis fungoides. Blood. 1997;90:1338-40.
27. Vermeer MH, Willemze R. Is Mycosis Fungoides exacerbated by fluoxetine? J Am Acad Dermatol. 1996;35:635-6.
28. Brandes LJ, La Bella FS, Warrington FC. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonist. J Natl Cancer Inst. 1991;83:1329-36.
29. Yosipovitch G, Szolar C, Hui XY, Maibach H. High-potency topical corticosteroid rapidly decrease histamine-induced itch but not thermal sensation and pain in human beings. J Am Acad Dermatol. 1996;35:118-20.
30. Bingham LG, Noble JW, Davis MD. Wet dressing used with topical corticosteroids for pruritic dermatoses: a retrospective study. J Am Acad Dermatol. 2009;60:792-800.
31. Phan NQ, Bernhard JD, Luger TA, et al. Antipruritic treatment with systemic mu-opioid receptor antagonists: A review. J Am Acad Dermatol. 2009;63:680-8.
32. Lidstone V, Thorns A. Pruritus in cancer patients. Cancer Treat Rev. 2001;27:305-12.
33. Barrios DM, Phillips GS, Geisler AN, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol. 2021;32(6):736-45.
34. Askling J, Linet M, Gridley G, et al. Cancer incidence in a population based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology. 2002;123:1428-35.
35. Pacheco M, Ferreira H, Silva C, et al. Antinuclear Antibody (ANA) and Anti-Mi-2-Alpha Positive Dermatomyositis Hinting a Cancer Diagnosis. Cureus. 2022;14(2):e21844. DOI:10.7759/cureus.21844
36. Sanders KM, Akiyama T. The vicious cycle of itch and anxiety. Neurosci Biobehav Rev. 2018;87:17-26.
37. Reich A, Trybucka K, Tracinska A, et al. Acne Itch: Do Acne Patients Suffer From Itching? Acta Derm Venereol. 2008;88(1):38-42.
38. Seité S, Moyal D. Using an emollient lotion to improve objective and subjective symptoms in atopic patients. 24th World Congress of dermatology. Abstract book. Milan, 2022.
39. Wohlrab J, Bangemann N, Kleine-Tebbe A, et al. Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer. Breast Cancer (Dove Med Press). 2014;6:115-22. DOI:10.2147/BCTT.S61699
2. Pavlis J, Yosipovitch G. Management of Itch in Atopic Dermatitis. Am J Clin Dermatol. 2018;19(3):319‑32. DOI:10.1007/s40257-017-0335-4
3. Lim YL, Chan YH, Yosipovitch G, Greaves MW. Pruritus is a common and significant symptom of acne. J Eur Acad Dermatol Venereol. 2008;22(11):1332-6.
DOI:10.1111/j.1468-3083.2008.02828.x
4. Rowe B, Yosipovitch G. Malignancy-associated pruritus. Eur J Pain. 2016;20(1):19-23. DOI:10.1002/ejp.760
5. Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol. 2012;67(4):760-8. DOI:10.1016/j.jaad.2011.12.021
6. Mills KC, Kwatra SG, Feneran AN, et al. Itch and pain in nonmelanoma skin cancer: pain as an important feature of cutaneous squamous cell carcinoma. Arch Dermatol. 2012;148(12):1422-3. DOI:10.1001/archdermatol.2012.3104
7. Chiang HC, Huang V, Cornelius LA. Cancer and itch. Semin Cutan Med Surg. 2011;30(2):107-12. DOI:10.1016/j.sder.2011.05.003
8. Lacouture ME (ed.). Dermatologic Principles and Practice in Oncology. 2014.
9. Миченко А.В., Круглова Л.С., Шатохина Е.А., и др. Дерматологическая токсичность ингибиторов EGFR: патогенетическое обоснование и алгоритм коррекции акнеподобной сыпи. Онкогематология. 2021;16(4):50-8 [Michenko AV, Kruglova LS, Shatokhina EA, et al. Dermatologicheskaia toksichnost' ingibitorov EGFR: patogeneticheskoe obosnovanie i algoritm korrektsii aknepodobnoi sypi. Onkogematologiia. 2021;16(4):50-8 (in Russian)]. DOI:10.17650/1818-8346-2021-16-4-50-58
10. Yosipovitch G. Chronic pruritus: A paraneoplastic sign. Dermatol Ther. 2010;23:590-6.
11. Jones EA, Bergasa NV. Why do cholestatic patients itch? Gut. 1996;38:644-5.
12. Wang H, Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol. 2010;49:1-11.
13. Naser AY, Hameed AN, Mustafa N, et al. Depression and Anxiety in Patients With Cancer: A Cross-Sectional Study. Front Psychol. 2021;12:585534. DOI:10.3389/fpsyg.2021.585534
14. Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment (Review). Oncol Lett. 2015;9(4):1509-14. DOI:10.3892/ol.2015.2944
15. Schmelz M, Schmidt R, Weidner C, et al. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol. 2003;89:2441-8.
16. Steinhoff M, Bienenstock J, Schmelz M, et al. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol. 2006;126:1705-18.
17. Parker F. Structure and function of skin. In: Goldma L, Bennett JC (ed.). Cecil Textbook of Medicine. 21st ed. Philadelphia: Saunders, 2000; p. 2266.
18. Mir A, Agim NG, Kane AA, et al. Giant Congenital Melanocytic Nevus Treated With Trametinib. Pediatrics. 2019;143(3):e20182469. DOI:10.1542/peds.2018-2469
19. Yuan T, Lu XH, Tang B Mr, et al. Differences in clinical characteristics and lesion proteomics between inflammatory linear verrucous epidermal nevus and local verrucous epidermal nevus. J Proteomics. 2022;260:104554. DOI:10.1016/j.jprot.2022.104554
20. Veraldi S, Bocor M, Gianotti R, Gasparini G. Multiple eruptive dermatofibromas localized exclusively to the buttock. Int J Dermatol. 1991;30(7):507-8.
DOI:10.1111/j.1365-4362.1991.tb04875.x
21. Husain Z, Ho JK, Hantash BM. Sign and pseudo-sign of Leser-Trélat: case reports and a review of the literature. J Drugs Dermatol. 2013;12(5):e79-87. PMID: 23652964.
22. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010;40(9):828-34. DOI:10.1111/j.1365-2362.2010.02334.x
23. Villafranca JJ, Siles MG, Casanova M, et al. Paraneoplastic pruritus presenting with Hodgkin’s lymphoma: a case report. J Med Case Rep. 2014;8:300. DOI:10.1186/1752-1947-8-300
24. Meyer N, Paul C, Misery L. Pruritus in Cutaneous T-cell Lymphomas: Frequent, Often Severe and Difficult to Treat. Acta Derm Venereol. 2010;90:12-7. DOI:10.2340/00015555-0789
25. Dummer R, Heald PW, Nestle FO, et al. Sezary syndrome T-cells clones display T-helper2 cytokines and express the accessory factor-1 (interferon gamma receptor beta-chain). Blood. 1996;88:1383-9.
26. Yamamoto T, Katayama I, Nishioka N. Role of mast cell and stem cell factor in hyperpigmented mycosis fungoides. Blood. 1997;90:1338-40.
27. Vermeer MH, Willemze R. Is Mycosis Fungoides exacerbated by fluoxetine? J Am Acad Dermatol. 1996;35:635-6.
28. Brandes LJ, La Bella FS, Warrington FC. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonist. J Natl Cancer Inst. 1991;83:1329-36.
29. Yosipovitch G, Szolar C, Hui XY, Maibach H. High-potency topical corticosteroid rapidly decrease histamine-induced itch but not thermal sensation and pain in human beings. J Am Acad Dermatol. 1996;35:118-20.
30. Bingham LG, Noble JW, Davis MD. Wet dressing used with topical corticosteroids for pruritic dermatoses: a retrospective study. J Am Acad Dermatol. 2009;60:792-800.
31. Phan NQ, Bernhard JD, Luger TA, et al. Antipruritic treatment with systemic mu-opioid receptor antagonists: A review. J Am Acad Dermatol. 2009;63:680-8.
32. Lidstone V, Thorns A. Pruritus in cancer patients. Cancer Treat Rev. 2001;27:305-12.
33. Barrios DM, Phillips GS, Geisler AN, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol. 2021;32(6):736-45.
34. Askling J, Linet M, Gridley G, et al. Cancer incidence in a population based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology. 2002;123:1428-35.
35. Pacheco M, Ferreira H, Silva C, et al. Antinuclear Antibody (ANA) and Anti-Mi-2-Alpha Positive Dermatomyositis Hinting a Cancer Diagnosis. Cureus. 2022;14(2):e21844. DOI:10.7759/cureus.21844
36. Sanders KM, Akiyama T. The vicious cycle of itch and anxiety. Neurosci Biobehav Rev. 2018;87:17-26.
37. Reich A, Trybucka K, Tracinska A, et al. Acne Itch: Do Acne Patients Suffer From Itching? Acta Derm Venereol. 2008;88(1):38-42.
38. Seité S, Moyal D. Using an emollient lotion to improve objective and subjective symptoms in atopic patients. 24th World Congress of dermatology. Abstract book. Milan, 2022.
39. Wohlrab J, Bangemann N, Kleine-Tebbe A, et al. Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer. Breast Cancer (Dove Med Press). 2014;6:115-22. DOI:10.2147/BCTT.S61699
________________________________________________
2. Pavlis J, Yosipovitch G. Management of Itch in Atopic Dermatitis. Am J Clin Dermatol. 2018;19(3):319‑32. DOI:10.1007/s40257-017-0335-4
3. Lim YL, Chan YH, Yosipovitch G, Greaves MW. Pruritus is a common and significant symptom of acne. J Eur Acad Dermatol Venereol. 2008;22(11):1332-6.
DOI:10.1111/j.1468-3083.2008.02828.x
4. Rowe B, Yosipovitch G. Malignancy-associated pruritus. Eur J Pain. 2016;20(1):19-23. DOI:10.1002/ejp.760
5. Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol. 2012;67(4):760-8. DOI:10.1016/j.jaad.2011.12.021
6. Mills KC, Kwatra SG, Feneran AN, et al. Itch and pain in nonmelanoma skin cancer: pain as an important feature of cutaneous squamous cell carcinoma. Arch Dermatol. 2012;148(12):1422-3. DOI:10.1001/archdermatol.2012.3104
7. Chiang HC, Huang V, Cornelius LA. Cancer and itch. Semin Cutan Med Surg. 2011;30(2):107-12. DOI:10.1016/j.sder.2011.05.003
8. Lacouture ME (ed.). Dermatologic Principles and Practice in Oncology. 2014.
9. Michenko AV, Kruglova LS, Shatokhina EA, et al. Dermatologicheskaia toksichnost' ingibitorov EGFR: patogeneticheskoe obosnovanie i algoritm korrektsii aknepodobnoi sypi. Onkogematologiia. 2021;16(4):50-8 (in Russian). DOI:10.17650/1818-8346-2021-16-4-50-58
10. Yosipovitch G. Chronic pruritus: A paraneoplastic sign. Dermatol Ther. 2010;23:590-6.
11. Jones EA, Bergasa NV. Why do cholestatic patients itch? Gut. 1996;38:644-5.
12. Wang H, Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol. 2010;49:1-11.
13. Naser AY, Hameed AN, Mustafa N, et al. Depression and Anxiety in Patients With Cancer: A Cross-Sectional Study. Front Psychol. 2021;12:585534. DOI:10.3389/fpsyg.2021.585534
14. Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment (Review). Oncol Lett. 2015;9(4):1509-14. DOI:10.3892/ol.2015.2944
15. Schmelz M, Schmidt R, Weidner C, et al. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol. 2003;89:2441-8.
16. Steinhoff M, Bienenstock J, Schmelz M, et al. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol. 2006;126:1705-18.
17. Parker F. Structure and function of skin. In: Goldma L, Bennett JC (ed.). Cecil Textbook of Medicine. 21st ed. Philadelphia: Saunders, 2000; p. 2266.
18. Mir A, Agim NG, Kane AA, et al. Giant Congenital Melanocytic Nevus Treated With Trametinib. Pediatrics. 2019;143(3):e20182469. DOI:10.1542/peds.2018-2469
19. Yuan T, Lu XH, Tang B Mr, et al. Differences in clinical characteristics and lesion proteomics between inflammatory linear verrucous epidermal nevus and local verrucous epidermal nevus. J Proteomics. 2022;260:104554. DOI:10.1016/j.jprot.2022.104554
20. Veraldi S, Bocor M, Gianotti R, Gasparini G. Multiple eruptive dermatofibromas localized exclusively to the buttock. Int J Dermatol. 1991;30(7):507-8.
DOI:10.1111/j.1365-4362.1991.tb04875.x
21. Husain Z, Ho JK, Hantash BM. Sign and pseudo-sign of Leser-Trélat: case reports and a review of the literature. J Drugs Dermatol. 2013;12(5):e79-87. PMID: 23652964.
22. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010;40(9):828-34. DOI:10.1111/j.1365-2362.2010.02334.x
23. Villafranca JJ, Siles MG, Casanova M, et al. Paraneoplastic pruritus presenting with Hodgkin’s lymphoma: a case report. J Med Case Rep. 2014;8:300. DOI:10.1186/1752-1947-8-300
24. Meyer N, Paul C, Misery L. Pruritus in Cutaneous T-cell Lymphomas: Frequent, Often Severe and Difficult to Treat. Acta Derm Venereol. 2010;90:12-7. DOI:10.2340/00015555-0789
25. Dummer R, Heald PW, Nestle FO, et al. Sezary syndrome T-cells clones display T-helper2 cytokines and express the accessory factor-1 (interferon gamma receptor beta-chain). Blood. 1996;88:1383-9.
26. Yamamoto T, Katayama I, Nishioka N. Role of mast cell and stem cell factor in hyperpigmented mycosis fungoides. Blood. 1997;90:1338-40.
27. Vermeer MH, Willemze R. Is Mycosis Fungoides exacerbated by fluoxetine? J Am Acad Dermatol. 1996;35:635-6.
28. Brandes LJ, La Bella FS, Warrington FC. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonist. J Natl Cancer Inst. 1991;83:1329-36.
29. Yosipovitch G, Szolar C, Hui XY, Maibach H. High-potency topical corticosteroid rapidly decrease histamine-induced itch but not thermal sensation and pain in human beings. J Am Acad Dermatol. 1996;35:118-20.
30. Bingham LG, Noble JW, Davis MD. Wet dressing used with topical corticosteroids for pruritic dermatoses: a retrospective study. J Am Acad Dermatol. 2009;60:792-800.
31. Phan NQ, Bernhard JD, Luger TA, et al. Antipruritic treatment with systemic mu-opioid receptor antagonists: A review. J Am Acad Dermatol. 2009;63:680-8.
32. Lidstone V, Thorns A. Pruritus in cancer patients. Cancer Treat Rev. 2001;27:305-12.
33. Barrios DM, Phillips GS, Geisler AN, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol. 2021;32(6):736-45.
34. Askling J, Linet M, Gridley G, et al. Cancer incidence in a population based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology. 2002;123:1428-35.
35. Pacheco M, Ferreira H, Silva C, et al. Antinuclear Antibody (ANA) and Anti-Mi-2-Alpha Positive Dermatomyositis Hinting a Cancer Diagnosis. Cureus. 2022;14(2):e21844. DOI:10.7759/cureus.21844
36. Sanders KM, Akiyama T. The vicious cycle of itch and anxiety. Neurosci Biobehav Rev. 2018;87:17-26.
37. Reich A, Trybucka K, Tracinska A, et al. Acne Itch: Do Acne Patients Suffer From Itching? Acta Derm Venereol. 2008;88(1):38-42.
38. Seité S, Moyal D. Using an emollient lotion to improve objective and subjective symptoms in atopic patients. 24th World Congress of dermatology. Abstract book. Milan, 2022.
39. Wohlrab J, Bangemann N, Kleine-Tebbe A, et al. Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer. Breast Cancer (Dove Med Press). 2014;6:115-22. DOI:10.2147/BCTT.S61699
Авторы
А.В. Миченко*1,2, А.Н. Львов1,2, Л.С. Круглова1, Д.В. Романов3,4, Е.А. Кузьма1
1 ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РФ, Москва, Россия;
2 Медицинский научно-образовательный центр Московского государственного университета им. М.В. Ломоносова, Москва, Россия;
3 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
4 ФГБНУ «Научный центр психического здоровья», Москва, Россия
*amichenko@mail.ru
1 Central State Medical Academy of the Administrative Department of the President of the Russian Federation, Moscow, Russia;
2 Medical Research and Educational Center of Lomonosov Moscow State University, Moscow, Russia;
3 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
4 Mental Health Research Center, Moscow, Russia
*amichenko@mail.ru
1 ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РФ, Москва, Россия;
2 Медицинский научно-образовательный центр Московского государственного университета им. М.В. Ломоносова, Москва, Россия;
3 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
4 ФГБНУ «Научный центр психического здоровья», Москва, Россия
*amichenko@mail.ru
________________________________________________
1 Central State Medical Academy of the Administrative Department of the President of the Russian Federation, Moscow, Russia;
2 Medical Research and Educational Center of Lomonosov Moscow State University, Moscow, Russia;
3 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
4 Mental Health Research Center, Moscow, Russia
*amichenko@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.